• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

European Commission Approves Chronic Kidney Disease Treatment Jardiance


Medicine developed in collaboration between Boehringer Ingelheim and Eli Lilly.

Chronic kidney disease. 3d illustration. Image Credit: Adobe Stock Images/Crystal light

Image Credit: Adobe Stock Images/Crystal light

Boehringer Ingelheim and Eli Lilly and Company have announced that Jardiance, a treatment for adults with chronic kidney disease (CKD), has been approved by the European Commission (EC). Based on results from SGLT2 inhibitor trial empa-kidney, the study found Jardiance reduced the risk of kidney disease progression or cardiovascular death by 28 percent, with a risk reduction of in hospitalization for any cause by 14 percent.

“Living with chronic kidney disease can have a drastic impact on patients and their family’s lives. CKD not only affects individuals but also society overall due to the high economic burden to healthcare systems,” said Carinne Brouillon, head of human pharma, Boehringer Ingelheim, in a company press release. “As we deepen our knowledge in interconnected cardio-renal-metabolic conditions, we are very excited about the approval and the potential for empagliflozin to play an essential role in helping patients, their physicians and healthcare systems.”

Reference: Jardiance® (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease. Business Wire. July 25, 2023. Accessed July 26, 2023. https://www.businesswire.com/news/home/20230718878355/en/Jardiance%C2%AE-empagliflozin-approved-in-the-EU-for-the-treatment-of-adults-with-chronic-kidney-disease

Related Videos
Related Content